Update on Cytokinetics

Update on Cytokinetics

Main remarks from Cytokinetics Inc. (Nasdaq: CYTK) last PRs and quarterly results are:

- Data from the phase II trial of ‘357 in myasthenia gravis are delayed until 1H of 2012.

- Amgen (Nasdaq: AMGN) is continuing the development of  Omecamtiv mercabil (OM) in its phase IIb safety and efficacy trial, now dubbed ATOMIC-AHF. Remember that top-line data won’t be released until 1H 2013.

- Cytokinetics is collecting data from a Part A study of its phase II PK, PD, multiple dose, safety and tolerability trial of ‘357 in patients with ALS who are not getting riluzole. Data will be presented at the 22nd International Symposium on ALS and Motor Neurone Diseases Meeting in Sydney, Australia on November 30 – December 2. It initiated a Part B in patients who are also receiving riluzole on Nov 1 with results expected in 1H of 2012

[Read more...]

Cytokinetics’ promising pipeline: a value stock for a long term investor.

Cytokinetics’ promising pipeline: a value stock for a long term investor.

(As originally published on Seeking Alpha on July 20, 2011). Also, check my latest update on Cytokinetics here.

Throughout this year, Cytokinetics’ shares have been moving between $1.12 and $2.96. During this time, the stock has been knocked down more than 60% and the recent turbulence in the market has not helped much either. This is a report on the main programs of the company plus some fundamental and technical analysis that will hopefully shed light on what a long term investor should expect from Cytokinetics.
[Read more...]